$20.6 Billion is the total value of Baker Brothers Advisors's 121 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 9.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Sell | Seagen Inc. | $7,249,714,000 | -9.7% | 46,893,364 | -0.8% | 35.27% | +0.0% |
| BGNE | BeiGene, Ltd.sponsored adr | $3,161,454,000 | -25.4% | 11,668,897 | 0.0% | 15.38% | -17.3% | |
| INCY | Buy | Incyte Corporation | $2,467,566,000 | +12.0% | 33,618,063 | +5.0% | 12.01% | +24.1% |
| KOD | Kodiak Sciences Inc. | $1,244,681,000 | -11.7% | 14,681,304 | 0.0% | 6.06% | -2.1% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $978,196,000 | +40.5% | 41,910,704 | 0.0% | 4.76% | +55.7% | |
| BMRN | BioMarin Pharmaceutical Inc. | $673,271,000 | +14.3% | 7,620,494 | 0.0% | 3.28% | +26.7% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $610,982,000 | -15.6% | 4,541,604 | 0.0% | 2.97% | -6.5% | |
| ARGX | argenx SEsponsored adr | $392,058,000 | +16.0% | 1,119,557 | 0.0% | 1.91% | +28.4% | |
| MRTX | Mirati Therapeutics, Inc. | $206,801,000 | -17.1% | 1,409,784 | 0.0% | 1.01% | -8.1% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $176,045,000 | -3.6% | 12,710,818 | 0.0% | 0.86% | +6.9% | |
| KYMR | Kymera Therapeutics, Inc. | $151,407,000 | +8.1% | 2,384,742 | 0.0% | 0.74% | +19.8% | |
| NVTA | Invitae Corporation | $150,768,000 | -46.3% | 9,873,488 | 0.0% | 0.73% | -40.5% | |
| ABCL | AbCellera Biologics Inc. | $149,438,000 | -28.6% | 10,450,180 | 0.0% | 0.73% | -21.0% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $127,043,000 | +6.2% | 1,499,213 | 0.0% | 0.62% | +17.7% | |
| PRLD | Prelude Therapeutics Inc. | $126,042,000 | -60.2% | 10,123,824 | 0.0% | 0.61% | -55.9% | |
| LEGN | Buy | Legend Biotech Corporationsponsored ads | $116,012,000 | -2.9% | 2,489,003 | +5.3% | 0.56% | +7.4% |
| PACB | Pacific Biosciences of California, Inc. | $111,404,000 | -19.9% | 5,444,963 | 0.0% | 0.54% | -11.3% | |
| GBT | Buy | Global Blood Therapeutics, Inc. | $97,023,000 | +18.3% | 3,314,765 | +3.0% | 0.47% | +31.1% |
| CERS | Cerus Corporation | $93,387,000 | +11.8% | 13,713,195 | 0.0% | 0.45% | +23.7% | |
| IGMS | IGM Biosciences, Inc. | $92,568,000 | -55.4% | 3,156,102 | 0.0% | 0.45% | -50.6% | |
| IMCR | Immunocore Holdings plcads | $86,310,000 | -7.6% | 2,520,730 | 0.0% | 0.42% | +2.4% | |
| TVTX | Buy | Travere Therapeutics, Inc. | $82,847,000 | +67.5% | 2,669,054 | +30.9% | 0.40% | +85.7% |
| New | Entrada Therapeutics, Inc. | $80,540,000 | – | 4,704,419 | +100.0% | 0.39% | – | |
| HRTX | Heron Therapeutics, Inc. | $74,242,000 | -14.6% | 8,131,678 | 0.0% | 0.36% | -5.5% | |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $71,342,000 | -36.0% | 21,169,805 | -3.1% | 0.35% | -29.0% |
| NRIX | Nurix Therapeutics, Inc. | $71,046,000 | -3.4% | 2,454,082 | 0.0% | 0.35% | +7.1% | |
| TIL | Instil Bio, Inc. | $66,621,000 | -4.3% | 3,893,700 | 0.0% | 0.32% | +5.9% | |
| MRUS | Merus N.V. | $64,792,000 | +44.5% | 2,037,469 | 0.0% | 0.32% | +59.9% | |
| HZNP | Horizon Therapeutics Public Ltd Co | $64,560,000 | -1.6% | 599,110 | 0.0% | 0.31% | +9.0% | |
| CCXI | Buy | ChemoCentryx, Inc. | $59,394,000 | +1053.3% | 1,631,266 | +441.6% | 0.29% | +1156.5% |
| IMTX | Immatics N.V. | $59,455,000 | +3.4% | 4,423,731 | 0.0% | 0.29% | +14.2% | |
| INSM | Insmed Incorporated | $58,729,000 | -1.1% | 2,156,001 | 0.0% | 0.29% | +9.6% | |
| NBIX | Neurocrine Biosciences, Inc. | $57,658,000 | -11.2% | 676,975 | 0.0% | 0.28% | -1.4% | |
| KRYS | Buy | Krystal Biotech, Inc. | $56,501,000 | +78.1% | 807,735 | +32.9% | 0.28% | +97.8% |
| VERV | Verve Therapeutics, Inc. | $52,227,000 | -21.6% | 1,416,530 | 0.0% | 0.25% | -13.0% | |
| Sell | Apellis Pharmaceuticals, Inc.note 3.5% 9/15/2026 | $47,968,000 | -16.2% | 31,754,000 | -32.1% | 0.23% | -7.2% | |
| VSTM | Verastem, Inc. | $44,058,000 | -33.4% | 21,491,630 | 0.0% | 0.21% | -26.5% | |
| Insmed Incorporatednote 0.75% 6/1/2028 | $43,336,000 | -1.1% | 40,000,000 | 0.0% | 0.21% | +9.3% | ||
| Sarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024 | $42,695,000 | -1.1% | 29,174,000 | 0.0% | 0.21% | +9.5% | ||
| RYTM | Rhythm Pharmaceuticals, Inc. | $38,555,000 | -23.6% | 3,863,239 | 0.0% | 0.19% | -15.3% | |
| KDNY | Buy | Chinook Therapeutics, Inc. | $38,069,000 | +56.8% | 2,334,102 | +22.6% | 0.18% | +72.9% |
| RARE | Ultragenyx Pharmaceutical Inc. | $37,373,000 | -6.8% | 444,444 | 0.0% | 0.18% | +3.4% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $36,866,000 | -27.5% | 9,830,877 | 0.0% | 0.18% | -19.7% | |
| ALKS | Buy | Alkermes plc | $34,890,000 | -7.9% | 1,500,000 | +22.1% | 0.17% | +2.4% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $32,951,000 | +3.3% | 2,799,577 | 0.0% | 0.16% | +14.3% | |
| DSGN | Design Therapeutics, Inc. | $30,758,000 | +45.7% | 1,436,636 | 0.0% | 0.15% | +61.3% | |
| TLIS | Buy | Talis Biomedical Corporation | $30,576,000 | -35.4% | 7,624,835 | +0.7% | 0.15% | -28.4% |
| FMTX | Forma Therapeutics Holdings, Inc. | $28,794,000 | -38.7% | 2,024,876 | 0.0% | 0.14% | -32.0% | |
| ZYME | Zymeworks Inc. | $28,002,000 | -43.6% | 1,708,472 | 0.0% | 0.14% | -37.6% | |
| BLUE | bluebird bio, Inc. | $24,972,000 | -47.7% | 2,499,715 | 0.0% | 0.12% | -42.4% | |
| ALGS | Aligos Therapeutics, Inc. | $24,647,000 | -23.5% | 2,076,400 | 0.0% | 0.12% | -14.9% | |
| OPT | Sell | Opthea Limitedsponsored ads | $24,115,000 | -10.9% | 3,196,191 | -5.5% | 0.12% | -1.7% |
| CRNX | Sell | Crinetics Pharmaceuticals, Inc. | $23,509,000 | +21.3% | 827,480 | -10.1% | 0.11% | +34.1% |
| XENE | Xenon Pharmaceuticals Inc. | $23,481,000 | +104.4% | 751,639 | 0.0% | 0.11% | +128.0% | |
| DBVT | DBV Technologies S.A.sponsored adr | $23,383,000 | -67.3% | 14,614,264 | 0.0% | 0.11% | -63.7% | |
| AXSM | Buy | Axsome Therapeutics, Inc. | $23,082,000 | +29.9% | 610,970 | +13.3% | 0.11% | +43.6% |
| AVTE | Buy | Aerovate Therapeutics, Inc. | $21,597,000 | -37.7% | 1,831,789 | +10.9% | 0.10% | -30.9% |
| New | 2seventy bio, Inc. | $21,356,000 | – | 833,236 | +100.0% | 0.10% | – | |
| FLGT | Sell | Fulgent Genetics, Inc. | $20,263,000 | -43.8% | 201,444 | -49.8% | 0.10% | -37.3% |
| NLTX | Neoleukin Therapeutics, Inc. | $18,421,000 | -33.3% | 3,821,740 | 0.0% | 0.09% | -25.6% | |
| OTIC | Buy | Otonomy, Inc. | $16,317,000 | +10.5% | 7,844,692 | +2.0% | 0.08% | +21.5% |
| AGLE | Aeglea BioTherapeutics, Inc. | $16,198,000 | -40.3% | 3,410,106 | 0.0% | 0.08% | -33.6% | |
| BCAB | BioAtla, Inc. | $16,195,000 | -33.3% | 825,000 | 0.0% | 0.08% | -26.2% | |
| REPL | Buy | Replimune Group, Inc. | $16,081,000 | +253.4% | 593,395 | +286.5% | 0.08% | +290.0% |
| Surrozen, Inc. | $16,100,000 | -9.0% | 2,500,000 | 0.0% | 0.08% | 0.0% | ||
| Sell | Tricida, Inc.note 3.5% 5/15/2027 | $14,828,000 | -52.7% | 27,500,000 | -63.3% | 0.07% | -47.8% | |
| ANAB | AnaptysBio, Inc. | $14,844,000 | +28.1% | 427,179 | 0.0% | 0.07% | +41.2% | |
| DICE Therapeutics, Inc. | $14,888,000 | -22.7% | 588,235 | 0.0% | 0.07% | -15.3% | ||
| AFMD | Buy | Affimed N.V. | $14,645,000 | +1340.0% | 2,653,169 | +1511.8% | 0.07% | +1675.0% |
| ACHL | Achilles Therapeutics plcsponsored ads | $12,983,000 | -35.7% | 2,591,366 | 0.0% | 0.06% | -29.2% | |
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $12,693,000 | -32.6% | 1,127,273 | 0.0% | 0.06% | -25.3% | |
| TCDA | Buy | Tricida, Inc. | $12,285,000 | +155.2% | 1,285,014 | +23.9% | 0.06% | +185.7% |
| SRPT | New | Sarepta Therapeutics, Inc. | $11,117,000 | – | 123,456 | +100.0% | 0.05% | – |
| RLMD | Buy | Relmada Therapeutics, Inc. | $11,155,000 | +111.8% | 495,113 | +146.3% | 0.05% | +134.8% |
| BCEL | Atreca, Inc. | $10,704,000 | -51.4% | 3,532,760 | 0.0% | 0.05% | -46.4% | |
| ATHA | Athira Pharma, Inc. | $10,507,000 | +38.9% | 806,367 | 0.0% | 0.05% | +54.5% | |
| ALT | Altimmune, Inc. | $9,820,000 | -19.0% | 1,072,038 | 0.0% | 0.05% | -9.4% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $9,623,000 | -23.4% | 10,300,000 | 0.0% | 0.05% | -14.5% | ||
| KRTX | Karuna Therapeutics, Inc. | $9,166,000 | +7.1% | 69,966 | 0.0% | 0.04% | +18.4% | |
| CYT | Cyteir Therapeutics, Inc. | $9,240,000 | -35.2% | 812,640 | 0.0% | 0.04% | -28.6% | |
| FGEN | New | FibroGen, Inc. | $8,180,000 | – | 580,150 | +100.0% | 0.04% | – |
| Tango Therapeutics, Inc. | $8,205,000 | -15.4% | 750,000 | 0.0% | 0.04% | -7.0% | ||
| EWTX | Edgewise Therapeutics, Inc. | $7,640,000 | -8.0% | 500,000 | 0.0% | 0.04% | +2.8% | |
| CBAY | CymaBay Therapeutics, Inc. | $7,336,000 | -7.4% | 2,170,464 | 0.0% | 0.04% | +2.9% | |
| MGNX | MacroGenics, Inc. | $7,103,000 | -23.4% | 442,579 | 0.0% | 0.04% | -14.6% | |
| NVAX | Sell | Novavax, Inc. | $6,891,000 | -69.4% | 48,168 | -55.7% | 0.03% | -65.7% |
| ITOS | Iteos Therapeutics, Inc. | $7,000,000 | +72.5% | 150,346 | 0.0% | 0.03% | +88.9% | |
| ALLK | Allakos Inc. | $6,883,000 | -90.8% | 703,050 | 0.0% | 0.03% | -89.9% | |
| TScan Therapeutics, Inc. | $6,413,000 | -46.0% | 1,425,000 | 0.0% | 0.03% | -40.4% | ||
| RETA | Reata Pharmaceuticals, Inc.cl a | $5,906,000 | -73.8% | 223,976 | 0.0% | 0.03% | -70.7% | |
| RVMD | Revolution Medicines, Inc. | $5,593,000 | -8.5% | 222,222 | 0.0% | 0.03% | 0.0% | |
| HRMY | Harmony Biosciences Holdings, Inc. | $5,270,000 | +11.2% | 123,600 | 0.0% | 0.03% | +23.8% | |
| NGM | NGM Biopharmaceuticals, Inc. | $5,168,000 | -15.7% | 291,801 | 0.0% | 0.02% | -7.4% | |
| ALEC | Alector, Inc. | $4,940,000 | -9.5% | 239,228 | 0.0% | 0.02% | 0.0% | |
| LIFE | aTyr Pharma, Inc. | $4,669,000 | -17.7% | 625,000 | 0.0% | 0.02% | -8.0% | |
| KURA | Kura Oncology, Inc. | $4,258,000 | -25.3% | 304,158 | 0.0% | 0.02% | -16.0% | |
| BMEA | Biomea Fusion, Inc. | $3,908,000 | -37.8% | 524,617 | 0.0% | 0.02% | -32.1% | |
| DNLI | Denali Therapeutics Inc. | $3,958,000 | -11.6% | 88,738 | 0.0% | 0.02% | -5.0% | |
| TCRR | Buy | TCR2 Therapeutics Inc. | $3,509,000 | +133.6% | 753,064 | +326.8% | 0.02% | +142.9% |
| GTH | Genetron Holdings Limitedads | $2,777,000 | -56.0% | 455,306 | 0.0% | 0.01% | -50.0% | |
| ALBO | Sell | Albireo Pharma, Inc. | $2,434,000 | -81.1% | 104,521 | -74.7% | 0.01% | -78.9% |
| AKRO | Akero Therapeutics, Inc. | $2,504,000 | -5.4% | 118,378 | 0.0% | 0.01% | 0.0% | |
| SNDX | Syndax Pharmaceuticals, Inc. | $2,424,000 | +14.6% | 110,729 | 0.0% | 0.01% | +33.3% | |
| VINC | Vincerx Pharma, Inc. | $2,460,000 | -37.0% | 241,379 | 0.0% | 0.01% | -29.4% | |
| CABA | Cabaletta Bio, Inc. | $2,509,000 | -68.8% | 662,063 | 0.0% | 0.01% | -65.7% | |
| KZR | Kezar Life Sciences, Inc. | $2,335,000 | +93.5% | 139,676 | 0.0% | 0.01% | +120.0% | |
| BNR | Burning Rock Biotech Limitedsponsored ads | $1,993,000 | -46.7% | 209,131 | 0.0% | 0.01% | -37.5% | |
| LPTX | Leap Therapeutics, Inc. | $1,813,000 | -19.2% | 559,705 | 0.0% | 0.01% | -10.0% | |
| HOOK | HOOKIPA Pharma Inc. | $1,632,000 | -60.4% | 700,481 | 0.0% | 0.01% | -55.6% | |
| GMDA | Gamida Cell Ltd. | $1,551,000 | -35.2% | 610,626 | 0.0% | 0.01% | -27.3% | |
| TARA | Protara Therapeutics, Inc. | $1,348,000 | -2.5% | 199,671 | 0.0% | 0.01% | +16.7% | |
| NEXI | NexImmune, Inc. | $1,356,000 | -69.5% | 294,117 | 0.0% | 0.01% | -65.0% | |
| Sera Prognostics, Inc. | $1,385,000 | -38.1% | 201,562 | 0.0% | 0.01% | -30.0% | ||
| FHTX | New | Foghorn Therapeutics Inc. | $1,030,000 | – | 45,027 | +100.0% | 0.01% | – |
| Surrozen, Inc.w exp 8/11/2026 | $958,000 | +0.8% | 833,333 | 0.0% | 0.01% | +25.0% | ||
| OYST | Oyster Point Pharma, Inc. | $1,122,000 | +54.1% | 61,424 | 0.0% | 0.01% | +66.7% | |
| LOGC | LogicBio Therapeutics, Inc. | $1,043,000 | -49.6% | 451,478 | 0.0% | 0.01% | -44.4% | |
| EVFM | Evofem Biosciences, Inc. | $1,013,000 | -49.1% | 2,697,110 | 0.0% | 0.01% | -44.4% | |
| INZY | Inozyme Pharma, Inc. | $730,000 | -41.1% | 106,999 | 0.0% | 0.00% | -20.0% | |
| PASG | Passage Bio, Inc. | $744,000 | -36.2% | 117,161 | 0.0% | 0.00% | -20.0% | |
| Bellicum Pharmaceuticals, Inc. | $371,000 | -49.0% | 249,123 | 0.0% | 0.00% | -33.3% | ||
| MREO | Exit | Mereo BioPharma Group plcads | $0 | – | -292,692 | -100.0% | -0.00% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -22,430 | -100.0% | -0.02% | – |
| Exit | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $0 | – | -4,500,000 | -100.0% | -0.02% | – | |
| AMYT | Exit | Amryt Pharma plcsponsored adr | $0 | – | -518,380 | -100.0% | -0.03% | – |
| AUPH | Exit | Aurinia Pharmaceuticals Inc. | $0 | – | -520,523 | -100.0% | -0.05% | – |
| MIRM | Exit | Mirum Pharmaceuticals, Inc. | $0 | – | -647,313 | -100.0% | -0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
| 4 | 2024-03-28 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.